Get the Stockscreener App
0.00
100.00%
-0.765
Genetic Technologies Ltd Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
See More
Previous Close:
$0.765
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$3.71M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
0.00
EPS:
-0.604
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$3.59
Genetic Technologies Ltd Adr Stock (GENE) Company Profile
Name
Genetic Technologies Ltd Adr
Sector
Industry
Phone
-
Address
-
Genetic Technologies Ltd Adr Stock (GENE) Latest News
Genetic Technologies faces NASDAQ equity shortfall - Investing.com India
Genetic Technologies joins "CancerIQ" platform - Investing.com
Genetic Technologies faces Nasdaq noncompliance issue - Investing.com
Genetic Technologies faces Nasdaq noncompliance issue By Investing.com - Investing.com UK
Genetic Technologies launches geneType on EasyDNA platform - Investing.com
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains? - Yahoo Finance
Genetic Technologies sets sights on U.S. market growth - Investing.com India
Genetic Technologies names new CFO and Company Secretary - Investing.com India
Genetic Technologies Ltd. ADR (GENE) Stock: A Year of Market Fluctuations - The InvestChronicle
Genetic Technologies CFO Steps Down By Investing.com - Investing.com India
HEICO shares target raised, keeps Buy rating on strong outlook By Investing.com - Investing.com India
Barclays maintains FedEx overweight rating, $350 target By Investing.com - Investing.com
Energizer stock PT raised to $375 at Deutsche Bank, reflecting revenue growth By Investing.com - Investing.com
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease - GlobeNewswire Inc.
Genetic Technologies to Host Investor Webinar By Investing.com - Investing.com India
Mastercard shareholders vote on board, executive pay, and proposals By Investing.com - Investing.com
Insmed shares target lifted by Evercore ISI on brensocatib optimism By Investing.com - Investing.com UK
Inozyme Pharma reports voting results, re-elects directors By Investing.com - Investing.com
BM Technologies reports annual meeting results By Investing.com - Investing.com
Gilead's HIV prevention trial shows promise with zero infections By Investing.com - Investing.com
FSN E-commerce stock upgraded by ICICI Securities citing growth focus By Investing.com - Investing.com
Crest Nicholson shares target reduced by Deutsche Bank, margin pressures cited By Investing.com - Investing.com
Biomea Fusion stock downgraded at Barclays; price target slashed to $5 from $30 By Investing.com - Investing.com UK
Genetic Technologies Ltd. ADR (GENE) Stock: A Comprehensive 52-Week Review - The InvestChronicle
The Psychology of Genetic Technologies Ltd. ADR Inc. (GENE) Price Performance: Understanding Market Sentiment - The InvestChronicle
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid ... - Investing.com UK
Li-Cycle holdings director Mark Wellings sells shares worth over $36,000 - Investing.com
Hesai Group CFO Louis T. Hsieh steps down By Investing.com - Investing.com
GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. ... - The Globe and Mail
GMAB: 3 Biotech Stocks Gaining Altitude and Interest - StockNews.com
The 8 Best Penny Stocks On Webull (June 2024) - The Stock Dork
The Best Biotech Stocks to Buy - Morningstar
6 Best Genomics Stocks to Buy in 2024 - The Motley Fool
GMAB: Bank on the Future Returns With These 3 Biotech Stocks - StockNews.com
TEVA: 3 Smart Pharma Picks Serving Gains - StockNews.com
Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement - Investor's Business Daily
Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change - Yahoo Finance
GSK: 3 Pharma Stocks Flashing 'Buy' Signals in December - StockNews.com
Top 5 NASDAQ Genetics Stocks - Investing News Network
GSK: 3 Pharma Stocks on the RiseIt's Time to Buy Now - StockNews.com
A pharmacogenetic study of perampanel: association between rare variants of glutamate receptor genes and outcomes - Frontiers
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it - Stockhead
Gene Slade’s Journey in Mastering Sales and Transforming Businesses - CEOWORLD magazine
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Check Up: Almost half a billion US dollars raised to bring back mammoth, dodo, and Tassie tiger - Stockhead
The 20 European Biotech Companies to Watch in 2022 - Labiotech.eu
Syncona to acquire Applied Genetic Technologies Corporation - BioPharma-Reporter.com
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities? - Stockhead
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Start of demonstration experiment of algal breeding technology to solve climate change issues -Aiming to establish the world's first useful algae breeding technology by introducing genetic mutation through neutron irradiation- - NTT
Tech - GSK
Genetic Technologies Ltd Adr Stock (GENE) Financials Data
There is no financial data for Genetic Technologies Ltd Adr (GENE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.48%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):